-
Product Insights
Cognitive Impairment Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Cognitive Impairment Clinical Trials Market Report Overview In total there were 1,537 clinical trials conducted on cognitive impairment, as of February 2023, of which the majority of them were conducted in Asia-Pacific. The cognitive impairment clinical trial market research report provides an overview of the clinical trials scenario. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 &...
-
Sector Analysis
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Report Overview Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of acquired immune-mediated disorder that affects the myelin components of the peripheral nervous system. Â CIDP can be monophasic, relapsing, or progressive, developing over eight weeks. People with CIDP experience fatigue, muscle weakness, and a loss of feeling symmetrically in their arms and legs that tends to slowly worsen over time. The CIDP marketed and pipeline drugs market research report provides a...
-
Sector Analysis
PharmaFocus: Tauopathies–Global Market Analysis
Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical companies in particular. These are: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease (clinically referred to as bvFTD), and chronic traumatic encephalopathy (CTE). In these indications, symptoms often present as behavioral (e.g. disinhibition,...
-
Sector Analysis
Acute Ischemic Stroke: Epidemiology Forecast to 2027
A stroke occurs when blood to the brain is either blocked or interrupted by blood clots or ruptured blood vessels; this deprives the brain of oxygen and nutrients, ultimately leading to the death of brain cells. Acute ischemic stroke (AIS) occurs due to an obstructed blood vessel that supplies blood to the brain, and is the predominant type of stroke, accounting for approximately 65–90% of stroke cases across the US, Europe, and Asia. The major risk factors associated with the...
-
Sector Analysis
Digital Landscape: Multiple Sclerosis
The Digital Landscape Multiple Sclerosis report analyzes digital activities undertaken by Pharma in support of disease-modifying therapies for Multiple Sclerosis (MS).
-
Sector Analysis
Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027
Stroke is caused by the interruption of the blood supply to the brain, usually because a cerebral blood vessel ruptures and bleeds (hemorrhagic stroke) or is blocked by a clot (ischemic stroke), which obstructs blood flow and oxygen and nutrients from reaching the brain, causing death of the local brain tissue (infarction). Stroke is a leading cause of disability and death worldwide and a common cause of dementia, associated with significant social and economic impact. The acute ischemic stroke (AIS)...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.